Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy

NCT03387761 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]